Prior investigations suggested that frequent mutations and inactivation of the von Hoppel Lindau (VHL) gene, which is responsible for vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitor, is a major factor in RCC, specifically ccRCC. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.